Does the media favor ATNM or HCWB?

In the previous week, HCW Biologics had 9 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 10 mentions for HCW Biologics and 1 mentions for Actinium Pharmaceuticals. HCW Biologics' average media sentiment score of 0.54 beat Actinium Pharmaceuticals' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HCW Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LSTA or HCWB?

In the previous week, HCW Biologics had 8 more articles in the media than Lisata Therapeutics. MarketBeat recorded 10 mentions for HCW Biologics and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.94 beat HCW Biologics' score of 0.54 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lisata Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HCW Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate NNVC or HCWB?

HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 555.02%. Given HCW Biologics' higher probable upside, analysts plainly believe HCW Biologics is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NNVC or HCWB more profitable?

NanoViricides has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. NanoViricides' return on equity of -87.90% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% HCW Biologics -34.73% -486.87% -29.19%

Does the media favor NNVC or HCWB?

In the previous week, HCW Biologics had 9 more articles in the media than NanoViricides. MarketBeat recorded 10 mentions for HCW Biologics and 1 mentions for NanoViricides. HCW Biologics' average media sentiment score of 0.54 beat NanoViricides' score of 0.25 indicating that HCW Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HCW Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HCWB or DARE?

In the previous week, HCW Biologics had 7 more articles in the media than Dare Bioscience. MarketBeat recorded 10 mentions for HCW Biologics and 3 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.93 beat HCW Biologics' score of 0.54 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HCW Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRVO or HCWB more profitable?

HCW Biologics has a net margin of -34.73% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -136.08% -112.62% HCW Biologics -34.73% -486.87% -29.19%

Does the media favor CRVO or HCWB?

In the previous week, HCW Biologics had 8 more articles in the media than CervoMed. MarketBeat recorded 10 mentions for HCW Biologics and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat HCW Biologics' score of 0.54 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HCW Biologics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

HCW Biologics (HCWB) Competitors

$4.58 -0.41 (-8.22%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$4.78 +0.20 (+4.26%)

As of 07/1/2026 07:43 PM Eastern

Compare

HCWB vs. ATNM, LSTA, NNVC, DARE, and CRVO

Should you buy HCW Biologics stock or one of its competitors? MarketBeat compares HCW Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HCW Biologics include Actinium Pharmaceuticals (ATNM), Lisata Therapeutics (LSTA), NanoViricides (NNVC), Dare Bioscience (DARE), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

How does HCW Biologics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

HCW Biologics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	341.57	-$48.82M	-$0.75	N/A
HCW Biologics	$50K	109.00	-$7.96M	-$9.46	N/A

In the previous week, HCW Biologics had 9 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 10 mentions for HCW Biologics and 1 mentions for Actinium Pharmaceuticals. HCW Biologics' average media sentiment score of 0.54 beat Actinium Pharmaceuticals' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HCW Biologics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actinium Pharmaceuticals has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market.

Actinium Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 410.31%. HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 555.02%. Given HCW Biologics' higher probable upside, analysts plainly believe HCW Biologics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 9.1% of HCW Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Actinium Pharmaceuticals' return on equity of -100.85% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
HCW Biologics	-34.73%	-486.87%	-29.19%

Summary

HCW Biologics beats Actinium Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does HCW Biologics compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lisata Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market.

In the previous week, HCW Biologics had 8 more articles in the media than Lisata Therapeutics. MarketBeat recorded 10 mentions for HCW Biologics and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.94 beat HCW Biologics' score of 0.54 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HCW Biologics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lisata Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 346.43%. HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 555.02%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lisata Therapeutics has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Lisata Therapeutics' return on equity of -103.54% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
HCW Biologics	-34.73%	-486.87%	-29.19%

HCW Biologics has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	180.06	-$16.59M	-$1.86	N/A
HCW Biologics	$50K	109.00	-$7.96M	-$9.46	N/A

Summary

Lisata Therapeutics and HCW Biologics tied by winning 8 of the 16 factors compared between the two stocks.

How does HCW Biologics compare to NanoViricides?

NanoViricides (NYSE:NNVC) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 555.02%. Given HCW Biologics' higher probable upside, analysts plainly believe HCW Biologics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, HCW Biologics had 9 more articles in the media than NanoViricides. MarketBeat recorded 10 mentions for HCW Biologics and 1 mentions for NanoViricides. HCW Biologics' average media sentiment score of 0.54 beat NanoViricides' score of 0.25 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HCW Biologics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HCW Biologics has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
HCW Biologics	$50K	109.00	-$7.96M	-$9.46	N/A

NanoViricides has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

NanoViricides has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. NanoViricides' return on equity of -87.90% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
HCW Biologics	-34.73%	-486.87%	-29.19%

Summary

HCW Biologics beats NanoViricides on 9 of the 14 factors compared between the two stocks.

How does HCW Biologics compare to Dare Bioscience?

HCW Biologics (NASDAQ:HCWB) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

HCW Biologics has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	109.00	-$7.96M	-$9.46	N/A
Dare Bioscience	$1.03M	30.69	-$13.40M	-$0.95	N/A

Dare Bioscience has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Dare Bioscience's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Dare Bioscience	N/A	N/A	-46.22%

HCW Biologics has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

HCW Biologics currently has a consensus price target of $30.00, suggesting a potential upside of 555.02%. Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 373.93%. Given HCW Biologics' higher probable upside, research analysts clearly believe HCW Biologics is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, HCW Biologics had 7 more articles in the media than Dare Bioscience. MarketBeat recorded 10 mentions for HCW Biologics and 3 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.93 beat HCW Biologics' score of 0.54 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HCW Biologics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

HCW Biologics and Dare Bioscience tied by winning 8 of the 16 factors compared between the two stocks.

How does HCW Biologics compare to CervoMed?

CervoMed (NASDAQ:CRVO) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

HCW Biologics has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	10.15	-$26.97M	-$3.28	N/A
HCW Biologics	$50K	109.00	-$7.96M	-$9.46	N/A

CervoMed has a beta of -0.68, meaning that its stock price is 168% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market.

25.2% of CervoMed shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

HCW Biologics has a net margin of -34.73% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
HCW Biologics	-34.73%	-486.87%	-29.19%

In the previous week, HCW Biologics had 8 more articles in the media than CervoMed. MarketBeat recorded 10 mentions for HCW Biologics and 2 mentions for CervoMed. CervoMed's average media sentiment score of 0.93 beat HCW Biologics' score of 0.54 indicating that CervoMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HCW Biologics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CervoMed presently has a consensus price target of $22.60, suggesting a potential upside of 512.47%. HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 555.02%. Given HCW Biologics' higher possible upside, analysts clearly believe HCW Biologics is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CervoMed and HCW Biologics tied by winning 8 of the 16 factors compared between the two stocks.

Get HCW Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCWB vs. The Competition

Export

Metric	HCW Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.96M	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.15%
P/E Ratio	-0.08	21.28	27.67	25.27
Price / Sales	109.00	324.37	533.25	101.18
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	0.91	8.71	10.96	6.62
Net Income	-$7.96M	$23.87M	$3.57B	$336.83M
7 Day Performance	-31.85%	4.34%	2.88%	3.19%
1 Month Performance	-57.36%	6.62%	3.69%	0.86%
1 Year Performance	-81.69%	61.64%	34.39%	27.51%

HCW Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCWB HCW Biologics	4.0766 of 5 stars	$4.58 -8.2%	$30.00 +555.0%	-79.6%	$5.96M	$50K	N/A	40	News Coverage Stock Split Gap Down
ATNM Actinium Pharmaceuticals	1.9664 of 5 stars	$1.01 -1.0%	$5.00 +395.0%	-27.4%	$31.69M	$90K	N/A	30
LSTA Lisata Therapeutics	2.9714 of 5 stars	$3.44 -0.9%	$15.00 +336.0%	+17.5%	$31.33M	$170K	N/A	30
NNVC NanoViricides	0.2805 of 5 stars	$1.36 +3.8%	N/A	-3.6%	$31.26M	N/A	N/A	20
DARE Dare Bioscience	3.2612 of 5 stars	$2.08 +0.5%	$10.00 +380.8%	-11.0%	$31.16M	$1.03M	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCWB) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCW Biologics (HCWB) Competitors

HCWB vs. ATNM, LSTA, NNVC, DARE, and CRVO

How does HCW Biologics compare to Actinium Pharmaceuticals?

Summary

How does HCW Biologics compare to Lisata Therapeutics?

Summary

How does HCW Biologics compare to NanoViricides?

Summary

How does HCW Biologics compare to Dare Bioscience?

Summary

How does HCW Biologics compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCW Biologics (HCWB) Competitors

HCWB vs. ATNM, LSTA, NNVC, DARE, and CRVO

How does HCW Biologics compare to Actinium Pharmaceuticals?

Which has stronger earnings & valuation, ATNM or HCWB?

Does the media favor ATNM or HCWB?

Which has more volatility and risk, ATNM or HCWB?

Do analysts recommend ATNM or HCWB?

Do insiders & institutionals hold more shares of ATNM or HCWB?

Is ATNM or HCWB more profitable?

Summary

How does HCW Biologics compare to Lisata Therapeutics?

Do insiders and institutionals hold more shares of LSTA or HCWB?

Which has more volatility & risk, LSTA or HCWB?

Does the media favor LSTA or HCWB?

Do analysts prefer LSTA or HCWB?

Is LSTA or HCWB more profitable?

Which has higher valuation & earnings, LSTA or HCWB?

Summary

How does HCW Biologics compare to NanoViricides?

Do analysts rate NNVC or HCWB?

Does the media favor NNVC or HCWB?

Do insiders & institutionals believe in NNVC or HCWB?

Which has higher earnings and valuation, NNVC or HCWB?

Which has more volatility & risk, NNVC or HCWB?

Is NNVC or HCWB more profitable?

Summary

How does HCW Biologics compare to Dare Bioscience?

Which has better earnings & valuation, HCWB or DARE?

Is HCWB or DARE more profitable?

Which has more volatility & risk, HCWB or DARE?

Do analysts prefer HCWB or DARE?

Does the media refer more to HCWB or DARE?

Do insiders and institutionals hold more shares of HCWB or DARE?

Summary

How does HCW Biologics compare to CervoMed?

Which has better earnings and valuation, CRVO or HCWB?

Which has more risk & volatility, CRVO or HCWB?

Do insiders and institutionals have more ownership in CRVO or HCWB?

Is CRVO or HCWB more profitable?

Does the media favor CRVO or HCWB?

Do analysts prefer CRVO or HCWB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB vs. The Competition

HCW Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools